{"id":881,"date":"2026-04-23T23:49:33","date_gmt":"2026-04-23T23:49:33","guid":{"rendered":"https:\/\/decodepeptides.com\/?product=retatrutide-10mg"},"modified":"2026-05-29T01:10:58","modified_gmt":"2026-05-29T01:10:58","slug":"retatrutide-10mg","status":"publish","type":"product","link":"https:\/\/decodepeptides.com\/nl_nl\/product\/retatrutide-10mg\/","title":{"rendered":"Retatrutide 10mg"},"content":{"rendered":"

Retatrutide<\/strong> (LY3437943) is an acylated synthetic peptide engineered by Eli Lilly as the world’s first GIP\/GLP-1\/glucagon triple agonist<\/strong>. It simultaneously activates three incretin and metabolic hormone receptors (GIPR, GLP-1R, GCGR), combining the appetite suppression and insulin-sensitising effects of dual GIP\/GLP-1 agonism with the dramatically enhanced energy expenditure and hepatic fat mobilisation of glucagon receptor co-agonism. Its Phase II data \u2014 showing 24.2% body weight reduction<\/strong> at 48 weeks \u2014 is the highest ever recorded for a pharmacological agent in an obesity trial, surpassing semaglutide, tirzepatide, and approaching bariatric surgery outcomes.<\/p>\n

\n
\n
\u226599%<\/span>HPLC Purity<\/span><\/div>\n
10mg<\/span>Per Vial<\/span><\/div>\n
10+<\/span>Years Researched<\/span><\/div>\n
Acylated<\/span>Structure<\/span><\/div>\n<\/div>\n
\"Retatrutide\"Retatrutide<\/div>\n

Research Data<\/span><\/p>\n

Research Snapshot \u2014 Retatrutide<\/h2>\n

Key Mechanisms & Pathways<\/h3>\n
    \n
  • GLP-1R Agonism \/ CNS<\/strong>Suppresses NPY and AgRP in hypothalamic ARC\/PVN \u2014 reducing appetite drive. Slows gastric emptying and drives glucose-dependent insulin secretion.<\/li>\n
  • GIPR Agonism<\/strong>GIP receptor co-agonism synergistically amplifies GLP-1R-mediated weight loss, with additional effects on bone, kidney and cardiovascular tissue.<\/li>\n
  • GCGR Agonism \u2014 Key Differentiator<\/strong>Glucagon receptor activation increases resting energy expenditure via BAT thermogenesis (UCP-1), \u03b2-oxidation (CPT-1) and hepatic fat mobilisation \u2014 absent in GLP-1 mono-agonists.<\/li>\n
  • Brown Adipose Thermogenesis<\/strong>GCGR-driven UCP-1 upregulation in BAT uncouples mitochondrial respiration from ATP synthesis, converting energy to heat \u2014 increasing TDEE.<\/li>\n
  • Hepatic Steatosis Reversal<\/strong>GCGR-driven cAMP elevation in hepatocytes reduces liver fat via VLDL export and CPT-1-mediated lipid oxidation \u2014 the strongest NASH research signal of any GLP-1-class compound.<\/li>\n
  • Lean Mass Preservation<\/strong>Unlike severe caloric restriction, retatrutide maintained fat-to-lean mass ratio \u2014 a key variable in obesity research quality assessment.<\/li>\n<\/ul>\n

    Preclinical & Clinical Research Summary<\/h3>\n\n\n\n\n\n\n\n\n
    Research Area<\/th>\nKey Finding<\/th>\nSource<\/th>\n<\/tr>\n<\/thead>\n
    Phase II Weight Loss<\/td>\n\u221224.2% body weight at 48 weeks at 12mg dose \u2014 highest ever recorded for a pharmacological agent in Phase II.<\/td>\nJastreboff AM et al., 2023 \u2014 N Engl J Med<\/td>\n<\/tr>\n
    Dose-Response<\/td>\n4mg: \u221217.5%; 8mg: \u221222.8%; 12mg: \u221224.2%. Responder rate (\u22655% loss) at 12mg: >96%.<\/td>\nJastreboff AM et al., 2023 \u2014 N Engl J Med<\/td>\n<\/tr>\n
    Type 2 Diabetes<\/td>\nHbA1c reduced by 2.02% vs. 0.27% placebo; weight loss \u221216.94% at 24 weeks in T2D patients.<\/td>\nRosenstock J et al., 2023 \u2014 Lancet<\/td>\n<\/tr>\n
    NASH \/ Liver Fat<\/td>\nSignificant reduction in MRI-PDFF liver fat and fibrosis biomarkers \u2014 leading compound for cardiometabolic-hepatic research.<\/td>\nCusi K et al., 2023 \u2014 EASL Congress<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
    \n

    References<\/h3>\n
      \n
    1. Jastreboff AM et al. “Triple-Hormone-Receptor Agonist Retatrutide for Obesity \u2014 A Phase 2 Trial.” N Engl J Med<\/em>, 2023;389(6):514\u2013526.<\/li>\n
    2. Rosenstock J et al. “Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes.” Lancet<\/em>, 2023;402(10401):529\u2013544.<\/li>\n
    3. Coskun T et al. “LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss.” Cell Metab<\/em>, 2022;34(9):1234\u20131247.<\/li>\n
    4. Jastreboff AM et al. “Retatrutide \u2014 phase 3 program design and rationale.” Obesity<\/em>, 2024.<\/li>\n<\/ol>\n<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"

      Retatrutide (LY3437943) is a next-generation, once-weekly injectable peptide developed by Eli Lilly as a triple agonist of GLP-1, GIP, and Glucagon receptors. Phase 2 clinical trials demonstrated weight loss of up to 24% of body weight over 48 weeks \u2014 surpassing all currently available anti-obesity pharmacotherapies. This research-grade vial contains 10mg of Retatrutide as lyophilized powder.<\/p>","protected":false},"featured_media":2114,"comment_status":"open","ping_status":"closed","template":"","meta":{"inline_featured_image":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0},"product_brand":[],"product_cat":[59],"product_tag":[220,224,223,256,257,222,254,221,255,219],"class_list":["post-881","product","type-product","status-publish","has-post-thumbnail","product_cat-weight-management","product_tag-appetite-suppression","product_tag-fat-oxidation","product_tag-glp-1-agonist","product_tag-hplc-verified","product_tag-injectable-peptide","product_tag-insulin-sensitivity","product_tag-lyophilized-powder","product_tag-metabolic-health","product_tag-research-grade","product_tag-weight-loss","first","instock","shipping-taxable","purchasable","product-type-simple"],"_links":{"self":[{"href":"https:\/\/decodepeptides.com\/nl_nl\/wp-json\/wp\/v2\/product\/881","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/decodepeptides.com\/nl_nl\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/decodepeptides.com\/nl_nl\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/decodepeptides.com\/nl_nl\/wp-json\/wp\/v2\/comments?post=881"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/decodepeptides.com\/nl_nl\/wp-json\/wp\/v2\/media\/2114"}],"wp:attachment":[{"href":"https:\/\/decodepeptides.com\/nl_nl\/wp-json\/wp\/v2\/media?parent=881"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/decodepeptides.com\/nl_nl\/wp-json\/wp\/v2\/product_brand?post=881"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/decodepeptides.com\/nl_nl\/wp-json\/wp\/v2\/product_cat?post=881"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/decodepeptides.com\/nl_nl\/wp-json\/wp\/v2\/product_tag?post=881"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}